Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 2
---
 not permitted. The information in this prospectus speaks only as of the date of this prospectus unless the information
specifically indicates that another date applies, regardless of the time of delivery of this prospectus or of any sale of the securities
offered hereby. Our business, financial condition, results of operations, and prospects may have changed since that date. We do not take
any responsibility for, nor do we provide any assurance as to the reliability of, any information other than the information in this prospectus.
Neither the delivery of this prospectus nor the sale of the Depositary Shares means that information contained in this prospectus is correct
after the date of this prospectus. You should not consider this prospectus to be an offer or solicitation relating to the securities in
any jurisdiction in which such an offer or solicitation relating to the securities is not authorized. Furthermore, you should not consider
this prospectus to be an offer or solicitation relating to the securities if the person making the offer or solicitation is not qualified
to do so, or if it is unlawful for you to receive such an offer or solicitation.

Unless the context specifically
indicates otherwise, references in this prospectus supplement to “Biodexa Pharmaceuticals PLC,” “Biodexa,” “the
Company,” “we,” “our,” “ours,” “us,” “the Group,” or similar terms refer
to Biodexa Pharmaceuticals PLC and its consolidated subsidiaries.

We have not taken any action to permit a public offering of the Depositary Shares outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the Depositary Shares and the distribution of this prospectus outside of the United States.

| 1 |

<div align='center'>PRESENTATION OF FINANCIAL AND OTHER INFORMATION</div>

Our financial statements
are prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board
and adopted by the European Union. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly,
numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

We prepare our consolidated
financial statements in British pounds sterling. Except as otherwise stated, all monetary amounts in this prospectus are presented in
British pounds sterling.

In this prospectus, unless
otherwise specified or the context